News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
3,125 Results
Type
Article (799)
Company Profile (2)
Press Release (2324)
Multimedia
Podcasts (13)
Webinars (1)
Section
Business (1259)
Career Advice (20)
Deals (174)
Drug Delivery (10)
Drug Development (593)
Employer Resources (10)
FDA (86)
Job Trends (173)
News (1953)
Policy (147)
Tag
Academia (10)
Alliances (184)
ALS (2)
Alzheimer's disease (5)
Approvals (87)
Artificial intelligence (3)
Autoimmune disease (3)
Bankruptcy (2)
Best Places to Work (110)
BIOSECURE Act (2)
Biotechnology (1)
Breast cancer (1)
Cancer (10)
Cardiovascular disease (3)
Career advice (15)
CAR-T (5)
Cell therapy (19)
Clinical research (412)
Collaboration (10)
Compensation (3)
Complete response letters (1)
COVID-19 (13)
CRISPR (20)
C-suite (15)
Cystic fibrosis (34)
Data (10)
Diabetes (6)
Diagnostics (5)
Diversity, equity & inclusion (2)
Drug discovery (5)
Drug pricing (10)
Duchenne muscular dystrophy (4)
Earnings (357)
Editorial (2)
Employer branding (6)
Employer resources (8)
Events (447)
Executive appointments (14)
FDA (106)
Funding (14)
Gene editing (35)
Gene therapy (40)
GLP-1 (19)
Government (33)
Guidances (4)
Healthcare (42)
Huntington's disease (1)
IgA nephropathy (5)
Immunology and inflammation (6)
Infectious disease (13)
Intellectual property (1)
Interviews (3)
IPO (54)
Job creations (68)
Job search strategy (13)
Labor market (2)
Layoffs (4)
Leadership (1)
Legal (18)
Lung cancer (2)
Manufacturing (7)
Medical device (14)
Medtech (14)
Mergers & acquisitions (118)
Metabolic disorders (13)
Multiple sclerosis (2)
Neurodegenerative disease (5)
Neuroscience (16)
NextGen: Class of 2025 (51)
Non-profit (14)
Now hiring (2)
Obesity (7)
Opinion (13)
Pain (25)
Parkinson's disease (1)
Partnered (1)
Patents (1)
People (616)
Pharmaceutical (1)
Phase I (148)
Phase II (229)
Phase III (155)
Pipeline (22)
Policy (11)
Postmarket research (18)
Preclinical (34)
Radiopharmaceuticals (2)
Rare diseases (72)
Real estate (57)
Recruiting (4)
Regulatory (134)
Research institute (5)
Resumes & cover letters (5)
RSV (1)
Schizophrenia (2)
Series A (4)
Sickle cell disease (29)
Special edition (2)
Spinal muscular atrophy (1)
Startups (35)
Supply chain (1)
Tariffs (5)
The Weekly (13)
Vaccines (8)
Venture capital (3)
Weight loss (4)
Date
Today (2)
Last 7 days (3)
Last 30 days (15)
Last 365 days (235)
2025 (165)
2024 (270)
2023 (222)
2022 (231)
2021 (254)
2020 (260)
2019 (197)
2018 (183)
2017 (221)
2016 (137)
2015 (210)
2014 (79)
2013 (67)
2012 (88)
2011 (122)
2010 (67)
Location
Africa (13)
Alabama (1)
Asia (90)
Australia (19)
California (24)
Canada (9)
China (9)
Colorado (1)
Europe (498)
Illinois (4)
Japan (2)
Maryland (6)
Massachusetts (139)
Minnesota (1)
Montana (1)
New Hampshire (2)
New Jersey (2)
New York (3)
North Carolina (8)
Northern California (6)
Ohio (2)
Pennsylvania (5)
South America (13)
Southern California (13)
Texas (2)
United States (197)
Utah (1)
Washington State (4)
3,125 Results for "vertex".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Trial Failure of Vertex’s Next-Gen Pain Drug Mars Strong Q2 Earnings
Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and lack of alignment with the FDA regarding an expanded label for Journavx tempered analyst reactions, sending the stock down 13%.
August 5, 2025
·
3 min read
·
Dan Samorodnitsky
Diabetes
Vertex’s Cell Therapy Could Be ‘Functional Cure’ for Diabetes, but Market Prospects Uncertain
While BMO Capital Markets said that zimislecel is “highly encouraging” for type 1 diabetes, questions regarding its target population and Vertex’s execution hang over the cell therapy’s commercial potential.
June 23, 2025
·
2 min read
·
Tristan Manalac
Deals
Vertex, Enlaza Declare War on Autoimmune Disease in Potential $2B+ Pact
Vertex Pharmaceuticals commits $45 million upfront to leverage Enlaza Therapeutics’ War-Lock platform to create drug conjugates and T cell engagers for autoimmune diseases and gentler conditioning for sickle cell/beta thalassemia gene-editing therapy Casgevy.
September 2, 2025
·
2 min read
·
Heather McKenzie
Layoffs
After Axing Diabetes Asset, Vertex Lays Off 140 Staff
The layoffs will heavily affect Vertex’s operations in Rhode Island, where the biotech will consolidate three facilities into one.
June 11, 2025
·
2 min read
·
Tristan Manalac
Earnings
Vertex Shrugs Off Q1 Miss With ‘Strong’ Journavx Launch, Encouraging Pipeline Position
Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big PBMs to cover the non-opioid pain drug.
May 6, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Vertex to Participate in Upcoming September 2025 Investor Conferences
August 21, 2025
·
2 min read
Pain
Vertex’s Journavx Changes the Pain Treatment Landscape But Opioids Here to Stay
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a growing number of alternative approaches. Their ultimate uptake, however, remains to be seen.
February 24, 2025
·
9 min read
·
Tristan Manalac
Diabetes
Vertex Cuts Diabetes Asset, but Analysts Keen on Phase III Option
Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge loss for Vertex given that the company has a more advanced type 1 diabetes candidate in zimislecel.
March 31, 2025
·
4 min read
·
Annalee Armstrong
Pain
AlgoTx Stumbles in Non-Opioid Pain Trial Following Vertex’s Journavx Approval
AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still believes in the promise of its candidate as Vertex Pharmaceuticals’ first-in-class drug Journavx opens up the non-opioid space.
February 18, 2025
·
3 min read
·
Tristan Manalac
Press Releases
Vertex Reports Second Quarter 2025 Financial Results
August 5, 2025
·
20 min read
1 of 313
Next
